Black Diamond Therapeutics CEO Mark Velleca receives $2.9M in 2023
Black Diamond Therapeutics reports 2023 executive compensation
By ExecPay News
Published: April 24, 2024
Black Diamond Therapeutics reported fiscal year 2023 executive compensation information on April 24, 2024.
In 2023, four executives at Black Diamond Therapeutics received on average a compensation package of $1.9M, a 66% increase compared to previous year.
Average pay of disclosed executives at Black Diamond Therapeutics
Mark A. Velleca, Chief Executive Officer, received $2.9M in total. 88% of Velleca's compensation, or $2.6M, was in option awards. Velleca also received $114K in non-equity incentive plan, $180K in salary, as well as $64K in other compensation.
David M. Epstein, Chief Executive Officer, received a compensation package of $2M, which increased by 23% compared to previous year. 52% of the compensation package, or $1M, was in option awards.
Fang Ni, Chief Financial Officer, earned $1.5M in 2023, a 64% increase compared to previous year.
Sergey Yurasov, Chief Medical Officer, received $1.2M in 2023.
Related executives
You may also like
Source: SEC filing on April 24, 2024.